ROSEN, SKILLED INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for misleading statements regarding the reliability and safety of its G6 and G7 continuous glucose monitoring systems during the specified Class Period from July 26, 2024, to September 17, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit alleges that DexCom made unauthorized design changes to the G6 and G7 systems that compromised their reliability, posing health risks to users [5]. - It is claimed that DexCom overstated the enhancements and reliability of the G7 device, while downplaying the severity of issues related to the adulterated devices [5]. - The lawsuit indicates that these actions subjected DexCom to increased regulatory scrutiny and potential legal and financial repercussions [5]. Group 2: Investor Information - Investors who purchased DexCom securities during the Class Period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by December 29, 2025, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].